Eli Lilly disclosed a $3.5 billion investment to build a Lehigh Valley manufacturing complex that will produce retatrutide and other next‑generation obesity injectables. The new facility is designed to scale drug and device production for high-volume launches and to secure capacity for Lilly’s weight‑loss franchise. Lilly positioned the plant as a response to surging demand for GLP‑1/GIP class medicines and to buffer supply-chain risks that have plagued rapid rollouts. Company statements stressed integrated manufacturing for drug and delivery devices to support global commercialization.